Studies have demonstrated that docosahexaenoic acid (DHA) may suppress the expression and secretion of fractalkine through inhibition of the tumor necrosis factor-α signaling pathway in DKD patients, which improves inflammation and reduces oxidative stress [23]. This evidence concerns the gene CX3CL1 and diabetic kidney disease.